S100A1 gene therapy for heart failure: a novel strategy on the verge of clinical trials.
S100A1 gene therapy for heart failure: a novel strategy on the verge of clinical trials.
复制标题
S100A1 基因治疗心力衰竭:一种即将进入临床试验的新策略。
DOI:
10.1016/j.yjmcc.2010.08.012
复制
发表时间:
2011
影响因子:
5
通讯作者:
Most,Patrick
中科院分区:
文献类型:
--
作者:
Rohde,David;Brinks,Henriette;Ritterhoff,Julia;Qui,Gang;Ren,Shumei;Most,Patrick
Representing the common endpoint of various cardiovascular disorders, heart failure (HF) shows a dramatically growing prevalence. As currently available therapeutic strategies are not capable of terminating the progress of the disease, HF is still associated with a poor clinical prognosis. Among the underlying molecular mechanisms, the loss of cardiomyocyte Ca2+cycling integrity plays a key role in the pathophysiological development and progression of the disease. The cardiomyocyte EF-hand Ca2+sensor protein S100A1 emerged as a regulator both of sarcoplasmic reticulum (SR), sarcomere and mitochondrial function implicating a significant role in cardiac physiology and dysfunction. In this review, we aim to recapitulate the translation of S100A1-based investigation from first clinical observations over basic research experiments back to a near-clinical setting on the verge of clinical trials today. We also address needs for further developments towards “second-generation” gene therapy and discuss the therapeutic potential of S100A1 gene therapy for HF as a promising novel strategy for future cardiologists.
登录
查看更多内容
影响因子:
12.4
作者:
Pleger, ST;Remppis, A;Most, P
通讯作者:
Most, P
影响因子:
3.9
作者:
Gupta, Ramesh C.;Mishra, Sudhish;Sabbah, Hani N.
通讯作者:
Sabbah, Hani N.
影响因子:
3.4
作者:
Yamasaki, R;Berri, M;Granzier, H
通讯作者:
Granzier, H
影响因子:
--
作者:
Wright NT;Cannon BR;Zimmer DB;Weber DJ
通讯作者:
Weber DJ
影响因子:
4
作者:
Volkers,Mirko;Loughrey,ChristopherM;Macquaide,Niall;Remppis,Andrew;DeGeorgeJr,BrentR;Wegner,FredericV;Friedrich,Oliver;Fink,RainerHA;Koch,WalterJ;Smith,GodfreyL;Most,Patrick
通讯作者:
Most,Patrick